Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Apollomics Inc. - Warrant
(NQ:
APLMW
)
0.0101
-0.0004 (-3.81%)
Delayed Quote
Updated: 12:06 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apollomics Inc. - Warrant
< Previous
1
2
3
4
Next >
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
November 28, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
November 16, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
October 31, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
October 26, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
October 23, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
October 16, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
September 28, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
April 11, 2023
Dr. Redkar to discuss importance of HGF/cMET pathway, which can play critical role in origin of several cancers
From
Apollomics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
